Prof. Dr. med. habil. Dr. med. Halvard B. Bönig, M.A.

• Bonig H, Priestley GV, Nilsson LM, Jiang Y, Papayannopoulou T (2004) PTX sensitive signals in bone marrow homing of fetal and adult hemopoietic Progenitor cells, Blood 104:2299-2306.
• Bonig H, Priestley GV, Papayannopoulou T (2006) Hierarchy of molecular pathway usage in bone marrow homing and its shift by cytokines, Blood 107:79-86.
• Bonig H, Chang KH, Nakamoto B, Papayannopoulou T (2006) The laminin receptor p67 is preferentially expressed in human erythroid progenitors and guides their lodgment to bone marrow, Blood 108:1230-1233.
• Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou, T (2008) Increased numbers of circulating hematopoietic stem/progenitor cells (HSPC) are chronically maintained in patients treated with the CD49d blocking antibody Natalizumab, Blood 111:3439-3441.
• Hsieh YT*, Gang EJ*, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Syedmedi S, Klemm L, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bonig H*, Kim YM* (2013) VLA4 blockade eradicates drug resistant pre-B acute lymphoblastic leukemia. Blood 121:1814-8.       *equal contribution
• Featured in Newswatch, Cancer Discovery January 24, 2013, DOI: 10.1158/2159-8290.CD-RW2013-019.
• Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, Pettit AR, Levesque JP, Romagnoli B, Patel K, Chevalier E, Dembowsky K, Bonig H (2013) The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 27:2322-2331.
• Karpova D, Ritchey J, Holt M, Monlish D, Batoon L, Millard A, Spohn G, Wiercinska E, Chendamarai E, Yang W, Schuettpelz LG, Dembowsky K, Pettit AR, Rettig M, Bonig H*, DiPersio JF* (2017) Continuous blockade of CXCR4 results in dramatic mobilization and expansion of murine hematopoietic stem and progenitor cells. Blood 129:2939-2949.                                                                        *equal contribution
• Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Eissenber LG, Heier RF, Arnett SD, Meyers MJ, Prinsen MJ, Griggs DW, Trumpp A, Ruminski PG, Morrow DM, Bonig H, Link DC, DiPersio JF (2019) Targeting CXCR2 and VLA4 to mobilize hematopoietic stem cells. Journal of Clinical Investigation 129:2745-2759.
• Tirado-Gonzalez I, Descot A, Soetopo D, Nevmerzitskaya A, Schäffer A, Kur IM, Ewelina C, Wachtel C, Tsoukala I, Müller L, Schäfer AL, Weitmann M, Dinse P, Alberto E, Buck MC, Landry JJ, Baying B, Slotta-Huspenina J, Roseler J, Harter PN, Kubach AS, Meinel J, Elwakeel E, Strack E, Tran Quang C, Abdel-Wahab O, Schmitz M, Weiger A, Schmid T, Platzbecker U, Benes V, Ghysdael J, Bonig H, Goetze KS, Torhlin C, Ghosh S, Medyouf H (2021) AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates naive and treatment resistant leukemia. Cancer Discovery 11:2924-2943.
• Ehrend E, Manns P, Harenkamp S, Seifried E, Geisen C, Bonig H (2021) re-analytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing. Blood 138:814-817.

Vollständiges Schriftenverzeichnis